D.A. Davidson & CO. Buys Shares of 11,385 Anavex Life Sciences Corp. (NASDAQ:AVXL)

D.A. Davidson & CO. purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 11,385 shares of the biotechnology company’s stock, valued at approximately $122,000.

A number of other institutional investors have also made changes to their positions in AVXL. JPMorgan Chase & Co. lifted its stake in Anavex Life Sciences by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 1,191 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Anavex Life Sciences by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 1,671 shares during the last quarter. Foster Victor Wealth Advisors LLC raised its position in shares of Anavex Life Sciences by 5.6% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock valued at $405,000 after acquiring an additional 2,000 shares during the period. Opus Capital Group LLC boosted its stake in Anavex Life Sciences by 6.1% during the 4th quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company’s stock worth $373,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Carnegie Investment Counsel grew its holdings in Anavex Life Sciences by 4.7% during the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock valued at $825,000 after purchasing an additional 3,445 shares during the period. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Price Performance

NASDAQ AVXL opened at $7.85 on Friday. The stock’s 50-day moving average is $9.90 and its 200-day moving average is $7.83. Anavex Life Sciences Corp. has a one year low of $3.25 and a one year high of $14.44. The firm has a market cap of $667.72 million, a P/E ratio of -14.27 and a beta of 0.69.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on AVXL shares. HC Wainwright reiterated a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Tuesday, February 18th. D. Boral Capital restated a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.